Поиск

Автор

Ключевое слово

Коллекция

Дополнительно:

Период публикации

Научный руководитель

Оппонент

По вашему запросу найдено документов: 289

Страница 1 из 29

Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events

Ivanova, E., Asadullina, D., Rakhimov, R., Izmailov, A., Izmailov, Al., Gilyazova, G., Galimov, Sh., Pavlov, V., Khusnutdinova, E., Gilyazova, I. (2022)

related toxicity. Immune-related adverse events (irAEs) are a major cause of immune checkpoint inhibitors

Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma

Ivanova, Elizaveta, Asadullina, Dilara, Gilyazova, Gulshat, Rakhimov, Radmir, Izmailov, Adel, Pavlov, Valentin, Khusnutdinova, Elza, Gilyazova, Irina (2023)

higher grade of immune-related adverse events (p-value = 0.020). The AUC value for the miRNA-146a and mi

МЕСТНАЯ И ОБЩАЯ РЕАКЦИИ ПРИ ВВЕДЕНИИ ВАКЦИНЫ ПРОТИВ COVID-19

LOCAL AND SYSTEMIC ADVERSE REACTIONS FOLLOWING COVID-19 VACCINE

Zherebtsova, N.Yu., Kajdanek, T.V., Жеребцова, Н.Ю., Кайданек, Т.В. (2022)

LOCAL AND SYSTEMIC ADVERSE REACTIONS FOLLOWING COVID-19 VACCINE

ЭФФЕКТИВНОСТЬ ИНГИБИТОРА ТИРОЗИНКИНАЗ 1-ГО ПОКОЛЕНИЯ (СУНИТИНИБ) В ТЕРАПИИ МЕТАСТАТИЧЕСКОГО ПОЧЕЧНО-КЛЕТОЧНОГО РАКА В АЛЬТЕРНАТИВНЫХ РЕЖИМАХ ДОЗИРОВАНИЯ

EFFICACY OF THE 1ST GENERATION TYROSINE KINASE INHIBITOR SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ALTERNATIVE DOSING REGIMENS

МЕНЬШИКОВ, К. В., СУЛТАНБАЕВ, А. В., МУСИН, Ш. И., ИЗМАЙЛОВ, А. A., ЧАЛОВ, В. С., МЕНЬШИКОВА, И. А., СУЛТАНБАЕВА, Н. И., ПОПОВА, Е. В., ЛИПАТОВ, Д. О., MENSHIKOV, K. V., SULTANBAEV, A. V., MUSIN, SH. I., IZMAILOV, A. A., CHALOV, V. S., MENSHIKOVA, I. A., SULTANBAEVA, N. I., POPOVA, E. V., LIPATOV, D. O. (2022)

ADVERSE EVENTS

Адаптация и валидация шкалы непереносимости метотрексата MISS у детей с ювенильным идиопатическим артритом: одномоментное поперечное исследование

Customization and validation of the Methotrexate Intolerance Severity Score in children with juvenile idiopathic arthritis: a cross-sectional study

Жуков, С.С., Малиевский, В.А., Леонова, А.С., Zhukov, S.S., Malievskiy, V.A., Leonova, A.S. (2022)

ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ КОМБИНАЦИИ НОВЫХ БИОМАРКЕРОВ В ДОЛГОСРОЧНОЙ СТРАТИФИКАЦИИ НЕБЛАГОПРИЯТНЫХ ИСХОДОВ У ПАЦИЕНТОВ С ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST

PROGNOSTIC SIGNIFICANCE OF A COMBINATION OF NOVEL BIOMARKERS IN THE LONG-TERM STRATIFICATION OF ADVERSE OUTCOMES IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

ГАРЕЕВА, Д.Ф., ХАМИТОВА, А.Ф., ЛАКМАН, И.А., РОНЖИН, Р.П., ЗУЛКАРНЕЕВ, Р.Х., ПЛОТНИКОВА, М.Р., ТУЛБАЕВ, Э.Л., МОТЛОХ, Л.Д., ЗАГИДУЛЛИН, Н.Ш., GAREEVA, D.F., KHAMITOVA, A.F., LAKMAN, I.A., RONZHIN, R.P., ZULKARNEEV, R. KH., PLOTNIKOVA, M.R., TULBAEV, E.L., MOTLOСH, L.D., ZAGIDULLIN, N. SH. (2020)

OF ADVERSE OUTCOMES IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

·0017). Most treatment-emergent adverse events were grade 1 or 2. The most common grade 3 or worse treatment

SAFETY AND TOLERABILITY OF ONCE-WEEKLY ADMINISTRATION OF CTP-MODIFIED HUMAN GROWTH HORMONE (MOD-4023): 24-MONTH COMPLETE DATASET RESULTS OF A PHASE 2 STUDY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY

Zelinska, N., Skorodokb, J., Malievsky, O., Rosenfeldd, Ron G., Zadike, Zvi, Korenf, R., Vanderf, Sh., Hartf, G., Radziukg, K. (2016)

. Results: No severe AEs were reported during MOD-4023 treatment. A similar rate of adverse events

A RANDOMIZED PHASE 2 STUDY OF LONG-ACTING TRANSCON GH VS DAILY GH IN CHILDHOOD GH DEFICIENCY

Chatelain, Pierre, Malievskiy, Oleg, Radziuk, Klaudziya, Senatorova, Ganna, Abdou, Magdy O., Vlachopapadopoulou, Elpis, Skorodok, Yulia, Peterkova, Valentina, Leff, Jonathan A., Beckert, Michael (2017)

was not statistically different from 11.6 cm for Genotropin. Adverse events were mild to moderate, and most were

Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results

Maniatis, Aristides K., Thornton, Paul S., Nadgir, Ulhas M., Vlachopapadopoulou, Elpis, Malievskiy, Oleg, Aghajanova, Elena M., Korpal-Szczyrska, Maria, Woods, Katie A., Mao, Meng, Zhao, Carol, Abdelrahman, Sohair G., Huang, Eric A., Komirenko, Allison S., Shu, Aimee D., Shu, A.D., Hofman, Paul (2025)

remained stable throughout the trial. Adverse events were mostly mild or moderate and remained consistent

Страница 1 из 29